%0 Journal Article
%T Sodium-glucose cotransporter 2 inhibitors and death and heart failure in type 2 diabetes
%A Hidekatsu Yanai
%J Archive of "Annals of Translational Medicine".
%D 2017
%R 10.21037/atm.2017.09.22
%X The Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial demonstrated that one of sodium-glucose cotransporter 2 inhibitors (SGLT2i), empagliflozin, reduced all-cause death, death from cardiovascular causes and hospitalization for heart failure when given in addition to standard care in patients with type 2 diabetes at high cardiovascular risk (1), giving us a big surprise and a question to solve whether this result is a drug effect or a class effect
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733321/